Literature DB >> 19286245

Are total prostate-specific antigen serum levels in cirrhotic men different from those in normal men?

Fabio C Vicentini1, Luiz A A Botelho, Marcelo Hisano, Gustavo X Ebaid, Marcos Lucon, Antonio M Lucon, Miguel Srougi.   

Abstract

OBJECTIVES: To determine the serum total prostate-specific antigen (tPSA) levels in cirrhotic men and compare them with those in noncirrhotic men.
METHODS: We prospectively evaluated 113 cirrhotic patients listed for liver transplantation using the serum tPSA, total testosterone level, and Child-Pugh liver function score according to age and severity of liver disease. The tPSA levels were compared with those of 661 healthy men. The Mann-Whitney U test was used for statistical analysis, with a significance level of .05.
RESULTS: The median age of the cirrhotic and noncirrhotic patients was 55 years (range 28-70) and 58 years (range 46-70), respectively (P < .01). However, when stratified by age group (<49, 50-59, and >60 years), this difference was not significant. The median serum tPSA level was 0.3 ng/mL (range 0.04-9.9) and 1.3 ng/mL (range 0.04-65.8) in the cirrhotic and noncirrhotic group, respectively (P < .0001). Stratifying both groups according to age, the cirrhotic patients had significantly lower tPSA levels than did the noncirrhotic patients. According to the Child-Pugh score (A, B, and C), Child-Pugh class C patients had significantly lower tPSA levels than did Child-Pugh class A patients and also had lower testosterone levels than did Child-Pugh class A and B patients. The tPSA levels correlated significantly with the testosterone levels in the cirrhotic patients (P = .028).
CONCLUSIONS: The results of our study have shown that cirrhotic patients have approximately 4 times lower serum tPSA levels than noncirrhotic men. Patients with more severe liver disease have lower tPSA and testosterone levels than patients less affected. The tPSA levels in cirrhotic men are affected by the total testosterone levels.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19286245     DOI: 10.1016/j.urology.2009.01.015

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  6 in total

1.  The likelihood of having a serum PSA level of ≥2.5 ng/mL according to the degree of fatty liver disease in a screened population.

Authors:  Jong Hyun Yoon; Hee Jo Yang; Jae Heon Kim; Seung Whan Doo; Won Jae Yang; Jiyoung Hwang; Seong Sook Hong; Suyeon Park; Dae Yeon Cho
Journal:  Can Urol Assoc J       Date:  2015-12-14       Impact factor: 1.862

2.  Association between Liver Fibrosis and Serum PSA among U.S. Men: National Health and Nutrition Examination Survey (NHANES), 2001-2010.

Authors:  Anqi Wang; Mariana Lazo; H Ballentine Carter; John D Groopman; William G Nelson; Elizabeth A Platz
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-06-03       Impact factor: 4.254

3.  Lower urinary tract symptoms in patients with liver cirrhosis.

Authors:  Markus Margreiter; Birgit B Heinisch; Remy Schwarzer; Tobias Klatte; Shahrokh F Shariat; Arnulf Ferlitsch
Journal:  World J Urol       Date:  2014-05-06       Impact factor: 4.226

Review 4.  [Urological aspects in patients with liver cirrhosis].

Authors:  A Friedl; R Schwarzer; J Schneeweiss; C Brössner
Journal:  Urologe A       Date:  2016-01       Impact factor: 0.639

5.  Is there an association between serum prostate-specific antigen values and serum testosterone levels in healthy men?

Authors:  Mahmoud Mustafa; Rahim Horuz; Metin Celik; Akif Kucukcan
Journal:  Korean J Urol       Date:  2014-07-11

6.  High regenerative capacity of the liver and irreversible injury of male reproductive system in carbon tetrachloride-induced liver fibrosis rat model.

Authors:  Rostyslav V Bubnov; Maria V Drahulian; Polina V Buchek; Tamara P Gulko
Journal:  EPMA J       Date:  2017-10-11       Impact factor: 6.543

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.